{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:17:07Z","timestamp":1788326227446,"version":"build-2803163510"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Tenofovir amibufenamide (TMF) is a newly recommended first-line nucleos(t)ide analogues for chronic hepatitis B (CHB) in China. However, real-world evidence on its safety and effectiveness are limited. This study aimed to evaluate the short-term virological efficacy, biochemical response, as well as safety profile of TMF over 48 weeks in a real-world cohort of CHB individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-center retrospective cohort study, 129 treatment-na\u00efve CHB patients were administered TMF at 25\u2005mg daily. Clinical, virological, and biochemical parameters were gathered at baseline and at weeks 12, 24, and 48 for evaluation. The primary effectiveness endpoint was virological response (VR, HBV DNA &amp;lt;10 IU\/mL) after 48 weeks of treatment. Secondary endpoints included VR at other timepoints, alanine aminotransferase (ALT) normalization, and changes in renal parameters and lipid levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At week 48, 72.9% (94\/129) of patients achieved VR. Multivariate analysis identified lower baseline HBsAg levels, HBeAg negative status and non-cirrhotic status as independent predictors for achieving VR. The ALT normalization rate was 77.5% (100\/129) at week 48. One patient achieved HBsAg seroclearance. Regarding safety, no adverse events linked to the medication were observed. There were no statistically significant alterations in serum phosphorus, estimated glomerular filtration rate, serum creatinine, or lipid levels (triglycerides, total cholesterol, high-density lipoprotein and low-density lipoprotein) from baseline to week 48.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this single-arm observational cohort, TMF treatment achieved effective virological suppression and high rates of ALT normalization by week 48, with renal function and lipid levels remaining stable. Because the study lacked a comparator group, these findings should be regarded as observational. Comparative conclusions about the safety or superiority of TMF relative to tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) require dedicated head-to-head studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1956363","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:23:10Z","timestamp":1788322990000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness and safety of tenofovir amibufenamide in treatment-na\u00efve chronic hepatitis B: a 48-week retrospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Jiarui","family":"Zheng","sequence":"first","affiliation":[{"name":"Peking University People's Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People's Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Song","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People's Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Feng","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People's Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yandi","family":"Xie","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People's Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/s0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1016\/s1473-3099(24)00307-4","article-title":"Who's 2024 global hepatitis report","volume":"24","author":"Burki","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/s2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","author":"Razavi-Shearer","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1053\/j.gastro.2022.10.008","article-title":"Current best practice in hepatitis B management and understanding long-term prospects for cure","volume":"164","author":"Yardeni","year":"2023","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jhep.2024.12.004","article-title":"The 2024 updated who guidelines for the prevention and management of chronic hepatitis B: main changes and potential implications for the next major liver society clinical practice guidelines","volume":"82","author":"Wong","year":"2025","journal-title":"J Hepatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Easl 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: aasld 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3760\/cma.j.cn501113-20221204-00607","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)","volume":"30","year":"2022","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.2147\/dddt.S419084","article-title":"Effect of food on the pharmacokinetics of tenofovir amibufenamide: a phase I, randomized, open-label, two-period crossover trial in healthy adult subjects","volume":"17","author":"Liu","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/apt.16196","article-title":"Randomised clinical trial: safety, efficacy and pharmacokinetics of hs-10234 versus tenofovir for the treatment of chronic hepatitis B infection","volume":"53","author":"Zhang","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.14218\/JCTH.2022.00058","article-title":"96-week treatment of tenofovir amibufenamide and tenofovir disoproxil fumarate in chronic hepatitis B patients","volume":"11","author":"Liu","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3760\/cma.j.issn.1007-3418.2019.11.008","article-title":"Chinese guidelines on the management of liver cirrhosis","volume":"27","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5907","DOI":"10.3748\/wjg.v29.i44.5907","article-title":"Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: a real-world study","volume":"29","author":"Peng","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/apt.16611","article-title":"Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B","volume":"54","author":"Liu","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.14218\/JCTH.2024.00364","article-title":"Effectiveness and safety of tenofovir amibufenamide in the treatment of chronic hepatitis B: a real-world, multicenter study","volume":"13","author":"Li","year":"2025","journal-title":"J Clin Transl Hepatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1111\/jgh.14750","article-title":"Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia","volume":"34","author":"Kim","year":"2019","journal-title":"J Gastroen Hepatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/hep.28916","article-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1572827","DOI":"10.3389\/fphar.2025.1572827","article-title":"Relationship between nucleos(T)ide analogue antiviral response time and prognosis in chronic hepatitis B: conclusions depend on baseline viral load and hbeag status","volume":"16","author":"Huang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1151899","DOI":"10.3389\/fcimb.2023.1151899","article-title":"Factors associated with persistent positive in hbv DNA level in patients with chronic hepatitis B receiving entecavir treatment","volume":"13","author":"Li","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1764956","DOI":"10.3389\/fmed.2026.1764956","article-title":"Efficacy and safety of tenofovir alafenamide in hbeag-positive and negative chronic hepatitis B patients aged over 30 years with normal alt and detectable hbv DNA: a 96-week retrospective two-center study","volume":"13","author":"Li","year":"2026","journal-title":"Front Med (Lausanne)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.5009\/gnl240023","article-title":"Toward a functional cure for hepatitis B","volume":"18","author":"Lok","year":"2024","journal-title":"Gut Liver"},{"key":"B23","doi-asserted-by":"publisher","first-page":"101360","DOI":"10.1016\/j.coviro.2023.101360","article-title":"Hepatitis-B virus: replication cycle, targets, and antiviral approaches","volume":"63","author":"Nasser","year":"2023","journal-title":"Curr Opin Virol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/hep.32314","article-title":"Getting to hbv cure: the promising paths forward","volume":"76","author":"Fung","year":"2022","journal-title":"Hepatology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14218\/Jcth.2022.00289","article-title":"An ideal hallmark closest to complete cure of chronic hepatitis B patients: high-sensitivity quantitative hbsag loss","volume":"11","author":"Wang","year":"2023","journal-title":"J Clin Transl Hepato"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1093\/infdis\/jiab241","article-title":"Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B","volume":"224","author":"Hsu","year":"2021","journal-title":"J Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"Hbsag seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.4254\/wjh.v16.i12.1395","article-title":"Influence of nonalcoholic fatty liver disease on the therapeutic effect of nucleoside (acid) analogs for hepatitis B virus","volume":"16","author":"Li","year":"2024","journal-title":"World J Hepatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"105921","DOI":"10.1016\/j.jcv.2026.105921","article-title":"A machine learning model for predicting complete virological response in chronic hepatitis B patients receiving first-line nucleos(T)ide analogues therapy","volume":"183","author":"Yuan","year":"2026","journal-title":"J Clin Virol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"29269","DOI":"10.1097\/MD.0000000000029269","article-title":"One-Year efficacy of tenofovir alafenamide in patients with chronic hepatitis B an observational study","volume":"101","author":"Chen","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1165990","DOI":"10.3389\/fphar.2023.1165990","article-title":"Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3892\/etm.2021.10760","article-title":"Efficacy and safety of tenofovir alafenamide fumarate in nucleoside analogue treatment-naive patients with chronic hepatitis B","volume":"22","author":"Chen","year":"2021","journal-title":"Exp Ther Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/liv.15261","article-title":"Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naive chronic hepatitis B","volume":"42","author":"Lim","year":"2022","journal-title":"Liver Int"},{"key":"B34","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2018.05.009","article-title":"Normal on-treatment alt during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B","volume":"69","author":"Wong","year":"2018","journal-title":"J Hepatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cgh.2021.04.045","article-title":"Tenofovir alafenamide for drug-resistant hepatitis B: a randomized trial for switching from tenofovir disoproxil fumarate","volume":"20","author":"Byun","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1186\/s12879-025-11473-6","article-title":"Comparative effectiveness and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in patients with hbv-associated decompensated cirrhosis: insights from a retrospective analysis","volume":"25","author":"Chen","year":"2025","journal-title":"Bmc Infect Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"109285","DOI":"10.3748\/wjg.v31.i26.109285","article-title":"Tenofovir amibufenamide in chronic hepatitis B: lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch","volume":"31","author":"Zeng","year":"2025","journal-title":"World J Gastroenterol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1956363\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:23:13Z","timestamp":1788322993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1956363\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":37,"alternative-id":["10.3389\/fmed.2026.1956363"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1956363","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"article-number":"1956363"}}